Seed · Bruxelles, Belgique

The Missing Layer in Modern Healthcare.

  • Belgian HealthTech
  • Behavioral intelligence for treatment adherence
  • First randomised study validated
  • First pharma partnership under contract
  • Data architecture built for pathology-by-pathology scale
Clinical study
76.8%
Adherence rate achieved with Gratiago in GRACE-001 — at the level of the best published interventions.
Pharma partnership
1signed
Commercial contract with Théa Pharma Belux — glaucoma deployment 2026.
Public grant
€280Ksecured
Innoviris grant funding the behavioral intelligence platform development.
Pipeline
Q42026
Oncology pilot in final negotiation with a second pharmaceutical partner.
Investment thesis

The molecule never heals alone.

50% of chronic disease patients do not adhere to their treatment. Annual European cost exceeds €125 billion. It is the most underestimated blind spot in modern care.

Gratiago is the behavioral infrastructure that fills this gap. Our method is clinically validated, our first pharma deployment is under contract, and our data architecture is engineered for pathology-by-pathology scale.

We are raising a Seed round to accelerate European commercial deployment and finalise oncology and cardiology pilots.

Data Room

Access the investor file.

Secure access on validation. You will receive a magic link by email valid for 7 days, giving access to the full pitch deck, the detailed GRACE-001 study, the business plan, and audited financials.

By submitting this form, you agree to be contacted by Gratiago about your access request. Data processed in accordance with the GDPR.
✓

Request received.

Sevan or Alexandre will reply within 24 working hours with your personalised access link.

An error occurred. Please write directly to invest@gratiago.com.

Any question: invest@gratiago.com

This site is strictly reserved for qualified investors. The information provided is confidential and does not constitute a public offer or solicitation to purchase financial securities.